Final Conference Programme | Wednesday 22nd March 2017
08.00
Arrival & Registration
09.00
Opening Remarks
SESSION 1:
OPENING PLENARY SESSION
Moderator: John A. Flygare (Merck Inc., USA)
09.00-09.45
‘Biology and engineering of Cow ultralong CDR3 antibodies’
Vaughn Smider (Sevion Therapeutics, San Diego, California, USA)
09.45-10.30
‘The development of antibody pyrrolobenzodiazepine conjugates’
Philip Howard (MedImmune/Spirogen Ltd, London, UK)
10.30-11.00
Coffee Break & Posters
SESSION 2:
PLENARY
Moderator: Roger R. Beerli (NBE-Therapeutics Ltd., Basel, Switzerland)
11.00-11.45
‘Pre-clinical development of a Flt3 specific ADC (AGS62P1) for the treatment of acute myeloid leukemia (AML) utilizing site specific conjugation and a novel, potent, tubulin inhibiting payload’
Kendall Morrison (Agensys Inc., Santa Monica, California, USA)
11.45-12.30
‘Update on mirvetuximab soravtansine and ImmunoGen’s growing ADC pipeline’
John Lambert (ImmunoGen Inc., Waltham, Massachusetts, USA)
12.30-12.45
Moderator-led Session Discussion
12.45-14.00
Lunch Break & Posters
SESSION 3:
CONJUGATION
Moderator: John Lambert (ImmunoGen Inc., Waltham, Massachusetts, USA)
14.00-14.30
‘Development on novel bioconjugation technologies for ADCs’
Vijay Chudasama (University College London, London, UK)
14.30-15.00
‘Highly potent, anthracycline-based ADCs generated by enzymatic, site-specific conjugation’
Roger R. Beerli (NBE-Therapeutics Ltd., Basel, Switzerland)
15.00-15.30
‘Moving a chemo-enzymatic protein conjugation technology from benchtop to large scale production’
Gregory Bleck (Catalent Pharma Solutions, Somerset, New Jersey, USA)
15.30-15.45
Moderator-led Session Discussion
15.45-16.15
Tea Break & Posters
SESSION 4:
ANTIBODY DRUG CONJUGATES
Moderator: David Rabuka (Catalent Pharma Solutions, Somerset, New Jersey, USA)
16.15-16.45
‘A novel platinum (II)-based bifunctional ADC linker benchmarked using 89Zr-Desferal and Auristatin F conjugated Trastuzumab’
Eugen Merkul (LinXis Pharmaceuticals, Amsterdam, The Netherlands)
16.45-17.15
‘Enabling better Antibody Drug Conjugates’
Campbell Bunce and George Badescu (Abzena PLC, Cambridge, UK)
17.15-17.45
‘Glycan-conjugated ADCs come with significantly expanded therapeutic index compared to both marketed ADCs’
Floris van Delft, Brian Janssen, Inge Hurkmans, Remon van Geel, Jorge Verkade, Jorin Hoogenboom, Marloes, Wijdeven and Sander van Berkel (Synaffix BV, Oss, The Netherlands)
17.45-18.00
Moderator-led Session Discussion
18.00-19.00
ATDC 2017 Welcome Drinks Reception & Posters
